

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
17 November 2022 (17.11.2022)



(10) International Publication Number
WO 2022/240783 A1

(51) International Patent Classification:

A61P 1/16 (2006.01) *C12N 15/113* (2010.01)
A61P 3/10 (2006.01) *C12Q 1/6883* (2018.01)
A61K 31/7088 (2006.01)

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

(21) International Application Number:

PCT/US2022/028415

(22) International Filing Date:

10 May 2022 (10.05.2022)

(25) Filing Language:

English

(26) Publication Language:

English

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(30) Priority Data:

63/186,838 11 May 2021 (11.05.2021) US

(71) Applicant: **REGENERON PHARMACEUTICALS, INC.** [US/US]; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US).

(72) Inventors: **VERWEIJ, Niek**; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **SOSINA, Olukayode**; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **AKBARI, Parsa**; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **LOCKE, Adam**; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **BARAS, Aris**; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **LOTTA, Luca Andrea**; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US).

(74) Agent: **LEGAARD, Paul K.**; c/o Armstrong Teasdale LLP, 7700 Forsyth Blvd., Suite 1800, St. Louis, Missouri 63105 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: METHODS OF TREATING LIVER DISEASES WITH PHOSPHODIESTERASE 3B (PDE3B) INHIBITORS

(57) Abstract: The present disclosure provides methods of treating a subject having a liver disease or type 2 diabetes, and methods of identifying subjects having an increased risk of developing a liver disease or type 2 diabetes.



WO 2022/240783 A1